Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculaturePARKER, Rex A; QI HUANG; TESFAMARIAM, Belay et al.Atherosclerosis. 2003, Vol 169, Num 1, pp 19-29, issn 0021-9150, 11 p.Article

Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity : demonstrable differences in vitro and clinicallyNOOR, Mustafa A; FLINT, Oliver P; MAA, Jen-Fue et al.AIDS (London). 2006, Vol 20, Num 14, pp 1813-1821, issn 0269-9370, 9 p.Article

NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding proteinMCDONNELL, Patricia A; CONSTANTINE, Keith L; ADAM, Leonard P et al.Journal of medicinal chemistry (Print). 2006, Vol 49, Num 16, pp 5013-5017, issn 0022-2623, 5 p.Article

Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitorsGUOHUA ZHAO; TAUNK, Prakash C; KIRBY, Mark S et al.Bioorganic & medicinal chemistry letters (Print). 2005, Vol 15, Num 18, pp 3992-3995, issn 0960-894X, 4 p.Article

Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: Interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitorsMAGNIN, David R; ROBL, Jeffrey A; AIYING WANG et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 10, pp 2587-2598, issn 0022-2623, 12 p.Article

Role of the fatty acid binding protein mall in obesity and insulin resistanceMAEDA, Kazuhisa; UYSAL, K. Teoman; MAKOWSKI, Liza et al.Diabetes (New York, NY). 2003, Vol 52, Num 2, pp 300-307, issn 0012-1797, 8 p.Article

The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy : Cellular Mechanisms and Clinical ImplicationsFLINT, Oliver P; NOOR, Mustafa A; HRUZ, Paul W et al.Toxicologic pathology. 2009, Vol 37, Num 1, pp 65-77, issn 0192-6233, 13 p.Conference Paper

Discovery and preclinical profile of saxagliptin (BMS-477118) : A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesAUGERI, David J; ROBL, Jeffrey A; HAN, Song-Ping et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 15, pp 5025-5037, issn 0022-2623, 13 p.Article

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adultsNOOR, Mustafa A; PARKER, Rex A; O'MARA, Edward et al.AIDS (London). 2004, Vol 18, Num 16, pp 2137-2144, issn 0269-9370, 8 p.Article

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2FURUHASHI, Masato; TUNCMAN, Gürol; SULSKY, Richard et al.Nature (London). 2007, Vol 447, Num 7147, pp 959-965, issn 0028-0836, 7 p.Article

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitorsSIMPKINS, Ligaya M; BOLTON, Scott; ZHONG SUN et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 23, pp 6476-6480, issn 0960-894X, 5 p.Article